TOT BioPharm reported unaudited FY 2025 revenue of RMB 747.6 million and a net loss of RMB 100.4 million, with total comprehensive loss of RMB 101.8 million. As of 31 December 2025, the group reported current assets of RMB 560.9 million and non-current assets of RMB 698.4 million, against current liabilities of RMB 273.5 million and non-current liabilities of RMB 360.0 million, for total net assets of RMB 625.8 million. The company said the figures were extracted from latest unaudited management accounts and disclosed ahead of its expected audited FY 2025 annual results announcement on 18 March 2026, following Taipei Exchange disclosure requirements tied to substantial shareholder Center Laboratories, Inc. It also noted the unaudited information constitutes a profit forecast under the Takeovers Code in connection with the Offers referenced in earlier takeover-related documents, with an SFC waiver granted for certain reporting requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260303-12038958), on March 03, 2026, and is solely responsible for the information contained therein.